Streamlining GLP-1 Prior Auth in Wisconsin

The Challenge of GLP-1 Prior Authorization in Wisconsin

GLP-1 receptor agonists are among the most heavily prior authorization-managed drug categories, with indications for Type 2 Diabetes (T2D) often covered, while obesity indications face significant coverage variations across plans. Without automation, providers in Wisconsin experience high PA volumes, frequent step-therapy gates, and complex documentation requirements that vary significantly between the state's Medicaid MCOs and commercial insurers. This often leads to increased denial rates and administrative burden.

Klivira's Automated GLP-1 Prior Authorization Workflow

• **Indication Classification:** Klivira accurately identifies T2D versus obesity indications directly from EMR diagnosis and clinical context.
• **Per-Payer Obesity-Coverage Routing:** Our policy engine maintains real-time, per-payer obesity benefit status for Wisconsin-specific plans, routing requests appropriately.
• **Step Therapy Documentation Automation:** We pull essential clinical data, such as metformin trial history, BMI documentation, and comorbidity status, directly from FHIR-enabled EMRs.
• **Brand-Specific Routing:** Klivira applies specific PA criteria logic for different GLP-1 products, including Ozempic, Wegovy, Mounjaro, Zepbound, and Saxenda.
• **Specialty Pharmacy Fulfillment Integration:** Post-approval, many GLP-1 products require routing to a specialty pharmacy, which Klivira integrates into the workflow.
• **Patient Financial Counseling:** When an obesity indication is denied, Klivira can surface manufacturer copay programs and alternative coverage paths, enhancing patient support.

Navigating Wisconsin's Payer Landscape

Wisconsin's healthcare ecosystem includes a mix of state-specific Medicaid managed care organizations and national commercial payers, each with unique prior authorization portals and criteria. Klivira's platform is designed to adapt to this diverse environment, providing the flexibility to connect with various payer channels, including X12 278, NCPDP SCRIPT, and proprietary payer portals. This ensures that GLP-1 prior authorization requests are submitted accurately and efficiently, regardless of the specific payer in Wisconsin.

Evidence-Based Automation for GLP-1 Workflows

Klivira's automation for GLP-1 prior authorizations is grounded in industry benchmarks and clinical standards. The increasing volume of pharmacy ePA transactions, as tracked by sources like the CAQH Index, underscores the criticality of efficient processing. Our system incorporates criteria from established guidelines such as the ADA Standards of Care for T2D treatment algorithms, ensuring that clinical documentation aligns with payer requirements and best practices for medications like Ozempic and Mounjaro.

Seamless EMR Integration for Wisconsin Providers

Klivira integrates directly with major EMR systems using SMART on FHIR, enabling automated data extraction for GLP-1 prior authorization requests. This direct integration minimizes manual data entry, reduces errors, and accelerates the submission process for clinics and health systems across Wisconsin. By leveraging existing clinical data, Klivira ensures that all necessary information, such as BMI and A1C levels, is accurately captured and submitted for medications like Wegovy and Zepbound.